Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan 1;8(1):167-168.
doi: 10.1001/jamaoncol.2021.5605.

Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer

Lu Tian  1 , Bo Huang  2 , Lee-Jen Wei  3
Affiliations
Comment

Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer

Lu Tian et al. JAMA Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Comment in

Comment on

References

    1. Jabbour SK, Lee KH, Frost N, et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol. Published online June 4, 2021. doi: 10.1001/jamaoncol.2021.2301 - DOI - PMC - PubMed
    1. Huang B, Tian L, Talukder E, Rothenberg M, Kim DH, Wei LJ. Evaluating treatment effect based on duration of response for a comparative oncology study. JAMA Oncol. 2018;4(6):874–876. doi: 10.1001/jamaoncol.2018.0275 - DOI - PMC - PubMed
    1. Huang B, Tian L, McCaw ZR, et al. Analysis of response data for assessing treatment effects in comparative clinical studies. Ann Intern Med. 2020;173(5): 368–374. doi: 10.7326/M20-0104 - DOI - PMC - PubMed

MeSH terms

Substances